<DOC>
	<DOCNO>NCT01598129</DOCNO>
	<brief_summary>The purpose study investigate safety recommend dose later use oncolytic adenovirus CGTG-102 combination low-dose oral cyclophosphamide treatment advance cancer .</brief_summary>
	<brief_title>ONCOS-102 ( Previously CGTG-102 ) Therapy Advanced Cancers</brief_title>
	<detailed_description>CGTG-102 adenovirus arm granulocyte-macrophage colony stimulate factor ( GMCSF ) , potent stimulator immunological cell . With regard oncolytic virus , replication normal cell take place , therefore viruses CGTG-102 know cause disease . Further , date incidence pass virus human patient . Since virus require tumor cell multiply , event unlikely . To day 100 patient treat CGTG-102 . This clinical trial take place approximately 6 month . The study include 12 visit hospital , 1 screen visit , 9 injection visit include overnight stay hospital ( perform trial day 1 , 4 , 8 , 15 , 29 , 57 , 85 , 113 141 ) , 1 end treatment visit ( day 169 ) 1 end study visit ( day 190 ) . Oral treatment cyclophosphamide ( 1 pill per day ) start day first injection last visit day 169 .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>1 . Solid tumour refractory evidencebased oncological therapy . 2 . Age 18 year . 3 . At least one tumour mass measurable PET ( i.e . PETpositive lesion reliably assess SUVmax , typically feature long diameter ≥2 cm ) . 4 . Tumour injectable i.t . direct visualisation/palpation imagingguidance ( ultrasound ) . I.t . include intracavitary injection , particularly intraperitoneal intrapleural . 5 . Histological confirmation primary disease relapse . 6 . Patient give sign informed consent . 7. WHO performance score 01 life expectancy 3 month . 8 . Previous anticancer treatment least 1 month Day 1 . 9 . Tumour assess suitable biopsy . 10 . Hepatic , renal bone marrow function within normal limit target population indicate follow : Total bilirubin ≤ upper limit normal ( ULN ) . ASAT , ALAT ≤3.0 × ULN . Serum creatinine ≤1.5 x ULN . International normalise ratio ( INR ) ≤1.5 x ULN . Haematologic parameter : Patients transfuse meet haemoglobin platelet count entry criterion . Haemoglobin ≥10 g/dL Leucocytes ≥2.3 x 109/L Platelet count ≥7.5 x 109/L 1 . Use high dose systemic immune suppressive medication within 3 week anticipate first treatment . Note : patient take lowdose corticosteroid treatment nausea and/or take maintenance corticosteroid permit enrol . 2 . Known infection HIV know underlying genetic immunodeficiency disease might affect safety efficacy treatment . 3 . Treatment inject tumour ( ) radiotherapy , chemotherapy , surgery , investigational drug within 4 week prior first treatment . 4 . Recent thromboembolic event ( deep venous thrombosis , pulmonary embolism ) . 5 . Clinically significant active infection clinically significant medical condition consider high risk investigational new drug treatment ( e.g . pulmonary , neurological , cardiovascular , metabolic , clinically significant and/or rapidly accumulate pericardial effusion ) . 6 . Severe unstable cardiac disease . 7 . Known brain metastasis , glioma . Central nervous system malignancy , include carcinomatosis meningitis . 8 . Pulse oximetry oxygen saturation &lt; 90 % rest room air . 9 . Vaccination live virus ( i.e . measles , mumps , rubella , etc . ) &lt; 30 day prior first treatment . 10 . History hepatic dysfunction , cirrhosis hepatitis . 11 . Prior organ transplant . 12 . Pregnant lactating patient . 13 . Evidence coagulation disorder . 14 . Other condition , opinion investigator , might interfere study finding represent safety hazard patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>oncolytic virus</keyword>
</DOC>